In one trial, the upregulation of CXCL10 and interferon-α caused by such a vaccine promoted the trafficking of CD8+ T cells and CD68+ macrophages into the GBM site, thereby reducing active mitotic activity in the tumor [62]. The gene discussed is CXCL10; the disease is neoplasm.